1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients

BACKGROUND: Cytomegalovirus (CMV) is one of the most common infections after transplantation and continues to cause significant morbidity and mortality. Current guidelines recommend 3-6 months of post-transplant prophylaxis with 900mg daily of valganciclovir in heart transplant recipients. At our in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Huang, Glen, Davis, Matthew R, Beaird, Omer E, Carlson, Margrit, Gaynor, Pryce, Multani, Ashrit, Deng, Mario, Nsair, Ali, Schaenman, Joanna M
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Poster Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776552/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1295
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires